PENN-0795

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

Docket No.

### TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231	29079						
Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:							
COMPOSITION AND METHOD FOR MODULATING SOMATOLACTOGENIC FUNCTION							
and invented by:							
Clevenger and Kline							
f a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:							
Continuation Divisional Continuation-in-part (CIP) of prior application No.:							
Which is a:							
Continuation Divisional Continuation-in-part (CIP) of prior application No.:							
Which is a:							
Continuation Divisional Continuation-in-part (CIP) of prior application No.:							
Enclosed are:							
Application Elements							
1. 🛛 Filing fee as calculated and transmitted as described below							
2. Specification having pages and including the following:							
a. 🛛 Descriptive Title of the Invention							
b.   Cross References to Related Applications (if applicable)							
c. 🛛 Statement Regarding Federally-sponsored Research/Development (if applicable)							
d.  Reference to Microfiche Appendix (if applicable)							
e. 🗵 Background of the Invention							
f. 🛛 Brief Summary of the Invention							
g. 🛛 Brief Description of the Drawings (if drawings filed)							
h. 🛛 Detailed Description							
i. ⊠ Claim(s) as Classified Below							
j. 🛛 Abstract of the Disclosure							
, — · · · · · · · · · · · · · · · · · ·							

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. PENN-0795

Total Pages in this Submission

3. ☑ Drawing(s) (when necessary as prescribed by 35 USC 113)												
		a.		Formal b. 🛭 Informal Number of Sheets5								
4. ☑ Oath or Declaration												
		a.		Newly executed (original or copy)   Unexecuted								
		b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)									
i.		c.	☑ With Power of Attorney ☐ Without Power of Attorney									
		d.	DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).									
	5.		Incorporation By Reference (usable if Box 4b is checked)  The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.									
	6.		Computer Program in Microfiche									
	7.	×	Ger	Genetic Sequence Submission (if applicable, all must be included)								
		a.	X	Paper Copy								
b. 🛛 Computer Readable Copy												
c.   Statement Verifying Identical Paper and Computer Readable Copy												
Accompanying Application Parts												
	8. Assignment Papers (cover sheet & documents)											
	9.	.   37 CFR 3.73(b) Statement (when there is an assignee)										
	10.		☐ English Translation Document (if applicable)									
	11.		Information Disclosure Statement/PTO-1449   Copies of IDS Citations									
	12.		Preliminary Amendment									
	13.	×	★ Acknowledgment postcard									
	14.	×	☑ Certificate of Mailing									
		_		First Class								

**Application Elements (Continued)** 

was unintentional.

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. PENN-0795

Total Pages in this Submission

Accompanying Application Parts (Continued)							
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)					
16.		Small Entity Statement(s) - Specify Number of Statements Submitted:					
17.	×	Additional Enclosures (please identify below):					
		USPTO Credit Card Payment Form					
18.		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)  Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.  Warning					
An applicant who makes a request not to publish, but who subsequently files country or under a multilateral international agreement specified in 35 U.S.C. 12 must notify the Director of such filing not later than 45 days after the date of such foreign or international application. A failure of the applicant to provide within the prescribed period shall result in the application being regarded as unless it is shown to the satisfaction of the Director that the delay in submitting							

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. PENN-0795

Total Pages in this Submission

		Fee Calculat	tion and Trar	smittal			
For	CLAIMS AS FILED						
For	#Filed	#Allowed	#Extra		Rate		Fee
Total Claims	10	- 20 =	0	x	\$9.00		\$0.00
Indep. Claims	1	- 3 =	0	x	\$42.00		\$0.00
Multiple Dependent Claims (check if applicable)							
BASIC FEE							\$370.00
OTHER FEE (specify purpose) \$0.00							\$0.00
TOTAL FILING FEE							\$370.00
<ul> <li>□ A check in the amount of to cover the filing fee is enclosed.</li> <li>☑ The Commissioner is hereby authorized to charge and credit Deposit Account No. 50-1619 as described below. A duplicate copy of this sheet is enclosed.</li> <li>□ Charge the amount of as filing fee.</li> <li>☑ Credit any overpayment.</li> <li>☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.</li> <li>□ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,</li> </ul>							
pursuant to 37 C.F.R. 1.311(b).  Dated: December 21, 2001							
Dated: December 21,	2001		Re Li 66 M Te	ne Massey eg. No. 32,2 cata & Tyr E. Main S arlton, NJ el: 856-810	Licata 257 rrell P.C. Street 08053 0-1515	Signature	

#### CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No. EV001201295US Date of Deposit <u>December 21, 2001</u>

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Patent Application Transmittal Letter (2 copies);
- 2) Application consisting of 20 pages of Specification, including two (2) pages of Claims and one (1) page of Abstract;
- 3) Five (5) sheets of Informal Drawings;
- 4) Return Post Card;
- 5) Credit Card Payment Form in the amount of \$370.00;
- 6) Unexecuted Declaration and Power of Attorney;
- 7) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §\$1.821-1.825;
- 8) Sequence listing; and
- 9) Diskette containing computer readable copy of Sequence Listing.

	•		
Sauno	Street		
JANE	MASSEY	LICATA	

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

PENN-0795

Inventors:

Clevenger and Kline

Serial No.:

Not yet assigned

Filing Date:

Herewith

Examiner:

Not yet assigned

Group Art Unit:

Not yet assigned

Title:

Composition and Method for Modulating

Somatolactogenic Function

"Express Mail" Label No. EV001201295US Date of Deposit - December 21, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By <u>Gangan Luct</u> Typed Name: Jane Massey Licata, Reg. No. 32,257

#### BOX SEQUENCE

Assistant Commissioner for Patents Washington, DC 20231

Sir:

### STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

- I hereby state, in accordance with the requirements of 37 (XX) C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
- I hereby state that the submission filed in accordance with 37 CFR \$1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.

- ( ) I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR \$1.825(b), is the same as the amended Sequence Listing.
- I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,

govenoogiccon)

Jane Massey Licata Registration No. 32,257

Date: December 21, 2001

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515